Health Utilities Among Patients With Chronic Rhinosinusitis With Nasal Polyps: An Exploratory Analysis From the WAYPOINT Trial
Author(s)
Danny Gibson, MASc1, Agota Szende, PhD2, Emilija Veljanoska, MSc3, Sam Colman, MBios4, Santiago Zuluaga Sanchez, MSc5.
1Market Access and Pricing, AstraZeneca, Cambridge, United Kingdom, 2Market Access Consulting & HEOR, Fortrea, Leeds, United Kingdom, 3Market Access Consulting & HEOR, Fortrea, Munich, Germany, 4Market Access Consulting & HEOR, Fortrea, Sydney, Australia, 5Health Economics, Amgen, Uxbridge, United Kingdom.
1Market Access and Pricing, AstraZeneca, Cambridge, United Kingdom, 2Market Access Consulting & HEOR, Fortrea, Leeds, United Kingdom, 3Market Access Consulting & HEOR, Fortrea, Munich, Germany, 4Market Access Consulting & HEOR, Fortrea, Sydney, Australia, 5Health Economics, Amgen, Uxbridge, United Kingdom.
OBJECTIVES: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a highly prevalent and under-investigated condition, with limited evidence on health utilities across severity levels. This research aims to estimate utility values stratified by disease severity using data from a randomized controlled trial.
METHODS: Health utility values were derived from WAYPOINT (NCT04851964), a phase 3, randomized, double-blind, placebo-controlled trial of tezepelumab in patients with CRSwNP. Utilities, as reported at baseline and weeks 24 and 52, were calculated using a repeated measures model with visit and health state severity as covariates among all patients pooled across study arms. Validated preference-based instruments were used, including the [a] EQ-5D-5L (3L crosswalk from EQ-5D-5L), [b] SF-6D (mapped from SF-36), [c] EQ-5D-3L (mapped from SF-36), and [d] EQ-5D-3L (mapped from SNOT-22), all derived from published algorithms. Health state severity classification was based on patient’s SNOT-22 score (≤20: mild; 21-≤50: moderate; >50: severe). Trial inclusion criterion was a minimum SNOT-22 score of 30 at baseline, reflecting initial moderate-to-severe state.
RESULTS: Health utility values declined with increasing CRSwNP severity across all measures. The EQ-5D-5L utilities [a] (least squares means; standard errors [SE]) declined from 0.924 [0.010] in mild disease to 0.832 [0.008] in moderate and 0.677 [0.013] in severe disease. Corresponding SF-6D values [b] were 0.819 [0.008], 0.721 [0.006], and 0.641 [0.006], while utilities based on EQ-5D-3L mapped from SF-36 [c] were 0.691 [0.005], 0.630 [0.004], and 0.541 [0.006], respectively. The method of EQ-5D-3L mapped from the disease specific SNOT-22 [d] discriminated utilities most, with values of 0.816 [0.004], 0.699 [0.006], and 0.476 [0.008], respectively.
CONCLUSIONS: This study highlights the substantial impact of CRSwNP on health utilities across disease severity levels. Results can inform future health economic evaluations that evaluate new interventions aiming to improve outcomes in this patient population heavily affected by CRSwNP and facing limited available treatment options.
METHODS: Health utility values were derived from WAYPOINT (NCT04851964), a phase 3, randomized, double-blind, placebo-controlled trial of tezepelumab in patients with CRSwNP. Utilities, as reported at baseline and weeks 24 and 52, were calculated using a repeated measures model with visit and health state severity as covariates among all patients pooled across study arms. Validated preference-based instruments were used, including the [a] EQ-5D-5L (3L crosswalk from EQ-5D-5L), [b] SF-6D (mapped from SF-36), [c] EQ-5D-3L (mapped from SF-36), and [d] EQ-5D-3L (mapped from SNOT-22), all derived from published algorithms. Health state severity classification was based on patient’s SNOT-22 score (≤20: mild; 21-≤50: moderate; >50: severe). Trial inclusion criterion was a minimum SNOT-22 score of 30 at baseline, reflecting initial moderate-to-severe state.
RESULTS: Health utility values declined with increasing CRSwNP severity across all measures. The EQ-5D-5L utilities [a] (least squares means; standard errors [SE]) declined from 0.924 [0.010] in mild disease to 0.832 [0.008] in moderate and 0.677 [0.013] in severe disease. Corresponding SF-6D values [b] were 0.819 [0.008], 0.721 [0.006], and 0.641 [0.006], while utilities based on EQ-5D-3L mapped from SF-36 [c] were 0.691 [0.005], 0.630 [0.004], and 0.541 [0.006], respectively. The method of EQ-5D-3L mapped from the disease specific SNOT-22 [d] discriminated utilities most, with values of 0.816 [0.004], 0.699 [0.006], and 0.476 [0.008], respectively.
CONCLUSIONS: This study highlights the substantial impact of CRSwNP on health utilities across disease severity levels. Results can inform future health economic evaluations that evaluate new interventions aiming to improve outcomes in this patient population heavily affected by CRSwNP and facing limited available treatment options.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE495
Topic
Economic Evaluation
Disease
Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)